A phase II study of flavopiridol (alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Flavonoids
  • Pancreatic Neoplasms
  • Piperidines
  • Taxoids

abstract

  • The combination of flavopiridol and docetaxel has minimal activity and significant toxicity in this patient population. These results reflect the challenges of treating patients with PC in a second-line setting where the risk/benefit equation is tightly balanced.

publication date

  • June 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4053191

Digital Object Identifier (DOI)

  • 10.1159/000187135

PubMed ID

  • 19451750

Additional Document Info

start page

  • 404

end page

  • 9

volume

  • 9

number

  • 4